New study reveals crucial protein interactions in Duchenne Muscular Dystrophy, opening doors to more precise and effective ...

Exciting news in the biotech industry as positive phase 2 results for sevasemten in BMD drive long-term investment potential ...

Indore (Madhya Pradesh): An advanced centre for treating muscular dystrophy will soon be established at Chacha Nehru Children ...

Satralizumab is under clinical development by F. Hoffmann-La Roche and currently in Phase II for Duchenne Muscular Dystrophy.

Study results provide root explanations for how dystrophin functions on a molecular level, providing base-level insights into ...

A groundbreaking study has shed light on the complex interactions between dystrophin, a protein critical to muscle stability, and its partner protein, dystrobrevin, offering new pathways for ...

Dec. 16, 2024 — A novel drug holds promise for treating Duchenne muscular dystrophy (DMD), a rare genetic disorder that causes severe muscle degeneration. Researchers have discovered that an ...

Duchenne muscular dystrophy (DMD) is a devastating genetic disease that is generally diagnosed ... of neurodevelopmental diseases like autism and ADHD in the general population, which could lead to ...

Sarepta Therapeutics has followed through on its promise to file for accelerated approval of its gene therapy SRP-9001 for Duchenne muscular dystrophy ... four years after treatment, in addition ...